RemeGen Co., Ltd
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy 2023-02-28 09:16
RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA 2022-12-13 12:30
RemeGen's Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines 2022-11-17 08:00
RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients 2022-11-01 12:12
RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis 2022-10-13 08:00
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China 2022-09-19 21:00
Biotech Company RemeGen Commemorates International Self-Care Day with Health Initiatives 2022-07-25 11:00
RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting 2022-05-24 10:27
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome 2022-01-26 10:52
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome 2022-01-25 09:00
RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021 2021-12-15 09:35
RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment 2021-12-03 13:45
1 2